Tags : therapy


AbbVie and Neurocrine’s Oriahnn Receive the US FDA’s Approval as

Shots: The approval follows P-III ELARIS UF-I and ELARIS UF-II studies assessing Oriahnn (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules) vs PBO for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women for up to 24mos. The study met its 1EPs of clinically meaningful reduction in bleeding (defined as the […]Read More


Boehringer Ingelheim Signs a Second Research Collaboration with Saniona to

Shots: Saniona to receive up to $84.6 as milestones along with royalties on sales of the therapies. Boehringer Ingelheim to get an exclusive global right to research, develop, manufacture and commercialize therapeutics, identified under the collaboration The focus of the collaboration is to identify new therapies for schizophrenia by utilizing Saniona’s ion channel drug discovery […]Read More